The funds managed by Argos Soditic just announced the acquisition, together the management, of Cisbio Bioassays, a leading biotechnology company in the field of products and services for human in vitro diagnostics and pharmaceutical research, from the Belgian listed company Ion Beam Applications (IBA).
Through this Management Buy-Out (MBO) operation, Cisbio Bioassays becomes independent, with its spin-off departure from the Belgian group IBA.
The acquisition represents a major step forward in the history of Cisbio Bioassays. The company’s 25 years of experience have given it a recognized position as a major player in the world of diagnostics and biotechnologies. The arrival of Argos Soditic opens up prospects for strategic growth, and will enable the company to strengthen its market positions. Confident in Cisbio Bioassays' assets, Argos Soditic is accompanying the management team in implementing its strategic plan, focused on innovation, the launching of new products and international development.
The Kramer Levin teamed that advised Argos Soditic on the deal included Paris partner Christophe Gaschin, with assistance from associates Ramona Tudorancea, Séverine Gallet and Stanislas Marmion on the corporate aspects; partner Marco Plankensteiner on the merger control aspects; and by counsel Fabienne Arrighi on the employment aspects.